Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apont… Read more
Apontis Pharma AG (APPH) - Total Liabilities
Latest total liabilities as of June 2025: €12.37 Million EUR
Based on the latest financial reports, Apontis Pharma AG (APPH) has total liabilities worth €12.37 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Apontis Pharma AG - Total Liabilities Trend (2018–2024)
This chart illustrates how Apontis Pharma AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Apontis Pharma AG Competitors by Total Liabilities
The table below lists competitors of Apontis Pharma AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Community Investors Bancorp Inc
PINK:CIBN
|
USA | $302.05 Million |
|
EE-HWA Construction Co. Ltd
KQ:001840
|
Korea | ₩48.47 Billion |
|
Forge Group Inc.
PINK:FIGP
|
USA | $59.25 Million |
|
Linz Textil Holding AG
VI:LTH
|
Austria | €12.84 Million |
|
Chuang's China Investments Limited
F:CUG
|
Germany | €499.00 Million |
|
Signal Advance Inc
PINK:SIGL
|
USA | $3.93K |
|
Sun Peak Metals Corp
OTCQB:SUNPF
|
USA | $47.14K |
|
SaintMed Public Company Limited
BK:SMD
|
Thailand | ฿396.45 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Apontis Pharma AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apontis Pharma AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apontis Pharma AG (2018–2024)
The table below shows the annual total liabilities of Apontis Pharma AG from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €13.36 Million | -50.89% |
| 2023-12-31 | €27.20 Million | +48.72% |
| 2022-12-31 | €18.29 Million | +36.27% |
| 2021-12-31 | €13.42 Million | -48.84% |
| 2020-12-31 | €26.23 Million | +1.11% |
| 2019-12-31 | €25.94 Million | -6.70% |
| 2018-12-31 | €27.81 Million | -- |